Many years from now, you’re reclining in one of the many gray-blue armchairs that line the walls of a clinic. Your arm is propped up on a collapsible ...
Research roundup: Muscles from the lab, and more
We know you want to keep up with the relentless march of progress, but sometimes it’s just too relentless. So why not forget all those endlessly...
Will this protein help speed up clinical trials?
Biomarkers are a big deal in the clinical world: if as a doctor you’re able to take one simple measurement that allows you to look into a patient’s fu...
James Peyer: Why primary indications matter
“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs eve...
A peek inside the companies using AI to combat aging
Last Wednesday I attended the Buck Institute’s workshop on AI and Longevity, where speakers from several different organizations discussed how t...
In the media: Salamanders, supercentenarians and Silicon Valley
Can we “unlock a human’s inner salamander” with stem cell therapies? 3D-printed organs, uploaded brains, and disease-fighting nanobo...
In the media: Mouse mugshots, metabolic mayhem and metformin
Is a picture worth a thousand biomarkers? MouseAGE, the AI that wants to eyeball the age of rodents, thinks so. Dr. Craig Thomspon talks cancer metabo...
The joy of scientific discovery, converging disease mechanisms, and failures of communication: Dr Gordon Lithgow on the past and present of geroscience (part II)
Dr. Gordon Lithgow of the Buck Institute for Research on Aging, who spoke to us recently about the Caenorhabditis Intervention Testing Program, talks ...